Efficacy and safety outcome findings from the phase I/II open-label multi-center study using a drug targeting the EGFR exon 20 insertion oncogenic driver among patients with advanced non-small cell lung cancer (NSCLC) with and without brain metastases (who had previously been treated with chemotherapy) were reported at the 2019 ASCO Annual Meeting (Abstract 9007).
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
